Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 9/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26922558 | 0.90 | ALDH2 (0.61) | ALDH2ALDH1A1L3MBTL1MAPTKMT2A | |
| SCHEMBL9505080 | 0.87 | ALDH2 (0.59) | ALDH2POLBALDH1A1HPGDMAPT | |
| SCHEMBL6357749 | 0.84 | ALDH2 (0.61) | ALDH2POLBALDH1A1HPGDKMT2A | |
| SCHEMBL6362752 | 0.84 | KMT2A (0.60) | ALDH2POLBALDH1A1HPGDL3MBTL1 | |
| SCHEMBL17577444 | 0.84 | ALDH2 (0.57) | ALDH2POLBALDH1A1HPGDKMT2A | |
| SCHEMBL6255530 | 0.84 | ALDH2 (0.57) | ALDH2POLBALDH1A1HPGDKMT2A | |
| SCHEMBL26921872 | 0.83 | APEX1 (0.57) | POLBALDH1A1HPGDL3MBTL1KMT2A | |
| SCHEMBL14352881 | 0.81 | TRPV1 (0.56) | ALDH2POLBALDH1A1HPGD | |
| SCHEMBL21014324 | 0.81 | ALDH2 (0.48) | ALDH2POLBALDH1A1HPGDCA1 | |
| SCHEMBL16135585 | 0.81 | KMT2A (0.54) | ALDH2ALDH1A1HPGDTP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637427-B2 | ALDH-2 inhibitor compounds and methods of use | AMYGDALA NEUROSCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4540228-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | Amygdala Neurosciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244563-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637427-B2 | ALDH-2 inhibitor compounds and methods of use | ALDH3A1, ALDH1A1, ALDH1A2 | ALDH2 5/4885POLB 3061/4885ALDH1A1 2/4885 |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | ALDH2 2/4885POLB 2325/4885ALDH1A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.